Cargando…

Mildly Impaired Foot Control in Long-Term Treated Patients with Wilson’s Disease

Abnormal gait is a common initial symptom of Wilson’s disease, which responds well to therapy, but has not been analyzed in detail so far. In a pilot study, a mild gait disturbance could be detected in long-term treated Wilson patients. The question still is what the underlying functional deficit of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samadzadeh, Sara, Hefter, Harald, Tezayak, Osman, Rosenthal, Dietmar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788568/ https://www.ncbi.nlm.nih.gov/pubmed/35076542 http://dx.doi.org/10.3390/jfmk7010005

Ejemplares similares

Analysis of Single-Leg Hopping in Long-Term Treated Patients with Neurological Wilson’s Disease: A Controlled Pilot Study
por: Hefter, Harald, et al.
Publicado: (2022)

Analysis of Running in Wilson’s Disease
por: Samadzadeh, Sara, et al.
Publicado: (2022)

Comparing soleus injections and gastrocnemius injections of botulinum toxin for treating adult spastic foot drop: a monocentric observational study
por: Hefter, Harald, et al.
Publicado: (2021)

Differences in the Time Course of Recovery from Brain and Liver Dysfunction in Conventional Long-Term Treatment of Wilson Disease
por: Hefter, Harald, et al.
Publicado: (2023)

Cholinesterase Deficiency Syndrome—A Pitfall in the Use of Butyrylcholinesterase as a Biomarker for Wilson’s Disease
por: Arslan, Max, et al.
Publicado: (2022)

Pseudocholinesterase as a Biomarker for Untreated Wilson’s Disease
por: Hefter, Harald, et al.
Publicado: (2022)

The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia
por: Hefter, Harald, et al.
Publicado: (2021)

Effective Treatment of Neurological Symptoms with Normal Doses of Botulinum Neurotoxin in Wilson’s Disease: Six Cases and Literature Review
por: Hefter, Harald, et al.
Publicado: (2021)

Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop
por: Hefter, Harald, et al.
Publicado: (2021)

No Secondary Treatment Failure during Incobotulinumtoxin—A Long-Term Treatment Demonstrated by the Drawing of Disease Severity
por: Hefter, Harald, et al.
Publicado: (2023)

“Pseudo”-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study
por: Hefter, Harald, et al.
Publicado: (2023)

The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystonia
por: Hefter, Harald, et al.
Publicado: (2022)

The Impact of SARS-CoV-2 Pandemic Lockdown on a Botulinum Toxin Outpatient Clinic in Germany
por: Samadzadeh, Sara, et al.
Publicado: (2021)

Enhanced Effect of Botulinum Toxin A Injections into the Extensor Digitorum Brevis Muscle after Local Mechanical Leg Vibration: A Case Report
por: Hefter, Harald, et al.
Publicado: (2021)

Different Response Behavior to Therapeutic Approaches in Homozygotic Wilson’s Disease Twins with Clinical Phenotypic Variability: Case Report and Literature Review
por: Samadzadeh, Sara, et al.
Publicado: (2022)

The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation—A Monocentric Cross-Sectional Pilot Study
por: Hefter, Harald, et al.
Publicado: (2022)

Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia
por: Hefter, Harald, et al.
Publicado: (2019)

Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins
por: Hefter, Harald, et al.
Publicado: (2021)

Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure
por: Hefter, Harald, et al.
Publicado: (2022)

The Necessity of a Locally Active Antidote in the Clinical Practice of Botulinum Neurotoxin Therapy: Short Communication
por: Hefter, Harald, et al.
Publicado: (2022)

Exploring the Interplay between the Clinical and Presumed Effect of Botulinum Injections for Cervical Dystonia: A Pilot Study
por: Hefter, Harald, et al.
Publicado: (2023)

Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study
por: Hefter, Harald, et al.
Publicado: (2023)

Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature
por: Samadzadeh, Sara, et al.
Publicado: (2020)

Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA
por: Hefter, Harald, et al.
Publicado: (2020)

The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia
por: Samadzadeh, Sara, et al.
Publicado: (2020)

Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study
por: Hefter, Harald, et al.
Publicado: (2020)

Disease Progression of Idiopathic Cervical Dystonia in Spite of Improvement After Botulinum Toxin Therapy
por: Hefter, Harald, et al.
Publicado: (2020)

The impact of the initial severity on later outcome: retrospective analysis of a large cohort of botulinum toxin naïve patients with idiopathic cervical dystonia
por: Hefter, Harald, et al.
Publicado: (2020)

Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis
por: Hefter, Harald, et al.
Publicado: (2013)

Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin
por: Hefter, Harald, et al.
Publicado: (2022)

Post-Operative Quality of Life in Children with Severe Perthes Disease: Differences to Matched Controls and Correlation with Clinical Function
por: Palmen, Nina K., et al.
Publicado: (2014)

Cognitive impairment in Wilson's disease
por: Frota, Norberto Anizio Ferreira, et al.
Publicado: (2009)

Olfactory impairment in Wilson’s disease
por: Chen, Lei, et al.
Publicado: (2021)

Retinal Neurodegeneration in Wilson’s Disease Revealed by Spectral Domain Optical Coherence Tomography
por: Albrecht, Philipp, et al.
Publicado: (2012)

Long‐term adherence and response to botulinum toxin in different indications
por: Lee, John‐Ih, et al.
Publicado: (2020)

Long‐term outcome of Wilson's disease complicated by liver disease
por: Arai, Satoko, et al.
Publicado: (2021)

Wilson disease in Northern Portugal: a long-term follow-up study
por: Garrido, Isabel, et al.
Publicado: (2022)

A Case of Wilson's Disease in Patient with Mildly Elevated Liver Enzymes
por: Cho, Young-Hye, et al.
Publicado: (2011)

Selective Impairment of Attentional Networks of Alerting in Wilson's Disease
por: Han, Yongsheng, et al.
Publicado: (2014)

Ideal serum non-ceruloplasmin bound copper prediction for long-term treated patients with Wilson disease: a nomogram model
por: Tao, Zhuang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rhm89moh9b7v6nu9m25dm5pt3o